clinical trial · NCT06112314
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Advanced MelanomaBrenetafuspNivolumabNivolumab + Relatlimab
brief summary
This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanced melanoma.
started
Jun 5, 2024
primary completion
Oct 16, 2027
completion
Oct 16, 2027
last updated
Feb 25, 2026
official title
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol